Janssen H - Search Results

1

Birth cohort hepatitis C antibody prevalence in real-world screening settings in Ontario.

Biondi MJ, Hirode G, Capraru C, Vanderhoff A, Karkada J, Wolfson-Stofko B, Smookler D, Friedman SM, Bates K, Mazzulli T, Juan JV, Shah H, Hansen BE, Feld JJ, Janssen H. Biondi MJ, et al. Among authors: janssen h. Can Liver J. 2022 Aug 16;5(3):362-371. doi: 10.3138/canlivj-2021-0036. eCollection 2022 Aug. Can Liver J. 2022. PMID: 36133900 Free PMC article.

2

Long-term outcome of a covered vs. uncovered transjugular intrahepatic portosystemic shunt in Budd-Chiari syndrome.

Darwish Murad S, Luong TK, Pattynama PM, Hansen BE, van Buuren HR, Janssen HL. Darwish Murad S, et al. Liver Int. 2008 Feb;28(2):249-56. doi: 10.1111/j.1478-3231.2007.01649.x. Liver Int. 2008. PMID: 18251982

3

Thrombocytopenia and the risk of bleeding during treatment with peginterferon alfa and ribavirin for chronic hepatitis C.

Roomer R, Hansen BE, Janssen HL, de Knegt RJ. Roomer R, et al. J Hepatol. 2010 Sep;53(3):455-9. doi: 10.1016/j.jhep.2010.04.013. Epub 2010 Jun 1. J Hepatol. 2010. PMID: 20561709

4

Risk factors for infection during treatment with peginterferon alfa and ribavirin for chronic hepatitis C.

Roomer R, Hansen BE, Janssen HL, de Knegt RJ. Roomer R, et al. Hepatology. 2010 Oct;52(4):1225-31. doi: 10.1002/hep.23842. Hepatology. 2010. PMID: 20830784

5

Evaluation of transient elastography for fibrosis assessment compared with large biopsies in chronic hepatitis B and C.

Verveer C, Zondervan PE, ten Kate FJ, Hansen BE, Janssen HL, de Knegt RJ. Verveer C, et al. Liver Int. 2012 Apr;32(4):622-8. doi: 10.1111/j.1478-3231.2011.02663.x. Epub 2011 Oct 17. Liver Int. 2012. PMID: 22098684 Clinical Trial.

6

Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis.

van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, Duarte-Rojo A, Heathcote EJ, Manns MP, Kuske L, Zeuzem S, Hofmann WP, de Knegt RJ, Hansen BE, Janssen HL. van der Meer AJ, et al. Among authors: janssen hl. JAMA. 2012 Dec 26;308(24):2584-93. doi: 10.1001/jama.2012.144878. JAMA. 2012. PMID: 23268517

7

Sustained virological response to treatment in patients with chronic hepatitis C--reply.

van der Meer AJ, Hansen BE, Janssen HL. van der Meer AJ, et al. JAMA. 2013 Apr 10;309(14):1457. doi: 10.1001/jama.2013.2733. JAMA. 2013. PMID: 23571571 No abstract available.

8

Is there sufficient evidence to recommend antiviral therapy in hepatitis C?

van der Meer AJ, Wedemeyer H, Feld JJ, Hansen BE, Manns MP, Zeuzem S, Janssen HL. van der Meer AJ, et al. Among authors: janssen hl. J Hepatol. 2014 Jan;60(1):191-6. doi: 10.1016/j.jhep.2013.07.043. Epub 2013 Aug 20. J Hepatol. 2014. PMID: 23973931 Free article. Review.

9

Reply to: 'Evidence recommending antiviral therapy in hepatitis C'.

van der Meer AJ, Feld JJ, Zeuzem S, Janssen HL. van der Meer AJ, et al. J Hepatol. 2014 May;60(5):1102-3. doi: 10.1016/j.jhep.2014.01.008. Epub 2014 Jan 18. J Hepatol. 2014. PMID: 24445220 Free article. No abstract available.

10

Effect of thrombocytopenia on treatment tolerability and outcome in patients with chronic HCV infection and advanced hepatic fibrosis.

Maan R, van der Meer AJ, Hansen BE, Feld JJ, Wedemeyer H, Dufour JF, Zangneh HF, Lammert F, Manns MP, Zeuzem S, Janssen HL, de Knegt RJ, Veldt BJ. Maan R, et al. Among authors: janssen hl. J Hepatol. 2014 Sep;61(3):482-91. doi: 10.1016/j.jhep.2014.04.021. Epub 2014 Apr 26. J Hepatol. 2014. PMID: 24780302

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,357 results

Search Page